Biblio Discovery — Demo Discovery Service

5 results for "David Cunningham"

Showing 1–5 · 0.46 seconds · RSS

  1. Journal Article Full text

    International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

    Amy S. Ruppert; Jesse G. Dixon; Gilles Salles et al.

    Blood · 2020 · English · OpenAlex Scopus

    Great heterogeneity in survival exists for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL). Three scoring systems incorporating simple clinical parameters (age, lactate dehydrogenase, number/sites of involvement, stage, performance status) are widely used: the International…

  2. Journal Article Full text

    Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

    Catherine Thiéblemont; Tycel Jovelle Phillips; Hervé Ghesquières et al.

    Journal of Clinical Oncology · 2022 · English · OpenAlex Scopus

    PURPOSE: B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS: large B-cell lymphoma and at least two prior therapy lines (including anti-CD20 therapies) received subcutaneous…

  3. Journal Article Full text

    Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

    Paula Ghaneh; Daniel H. Palmer; Silvia Cicconi et al.

    ˜The œLancet. Gastroenterology & hepatology · 2022 · English · OpenAlex

    Background Patients with borderline resectable pancreatic ductal adenocarcinoma have relatively low resection rates and poor survival despite the use of adjuvant chemotherapy. The aim of our study was to establish the feasibility and efficacy of three different types of short-course neoadjuvant…

  4. Journal Article Full text

    Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

    John A. Bridgewater; Sian Alexandra Pugh; Tom Maishman et al.

    The Lancet Oncology · 2020 · English · OpenAlex Scopus

    Background The interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction in progression-free survival in patients allocated to cetuximab plus chemotherapy compared with those given chemotherapy alone. The focus of the…